ico therapeutics inc (ICOTF) Key Developments
iCo Therapeutics Inc. Reports Financial Results for the Nine Months Ended September 30, 2014
Nov 29 14
iCo Therapeutics Inc. reported financial results for the nine months ended September 30, 2014. For the period, the company incurred total comprehensive loss of $1,223,363 or $0.02 loss per share compared to a total comprehensive loss of $5,220,617 or $0.07 loss per share for the nine months ended September 30, 2013, representing a decrease of $3,997,254 in comprehensive loss. The decrease in net comprehensive loss is primarily a result of an increase in the carrying value of investment in Immune Pharmaceuticals, as well as a decrease in expenses associated with the iDEAL trial.
iCo Therapeutics Mulls Acquisitions
Nov 28 14
iCo Therapeutics Inc. (TSXV:ICO) is seeking acquisitions. Andrew Rae, President and Chief Executive Officer of iCo Therapeutics said, "We continue with that same model as we prepare for an oral Amphotericin B ("Oral AmpB") clinical study, while concurrently investigating the ability to expand our proprietary oral delivery platform and assessing complimentary assets which the Company may consider in-licensing or acquiring."
iCo Therapeutics Inc. Announces Advancement of Oral Amphotericin B Program
Oct 22 14
iCo Therapeutics Inc. announced next steps for its Oral Amphotericin B program. The company recently announced positive findings from its in vitro work involving samples from HIV/AIDS patients exposed to HAART therapy. iCo now plans to complete pre clinical studies and regulatory filings to move forward with an initial Phase 1A clinical trial, utilizing approximately $700,000 of funding and technological advice from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), under the Canadian HIV Technology Development (CHTD) Program. The preparation and regulatory filings are expected to be completed in the second half of 2015, with initiation of a Phase 1A study early in the first quarter of 2016. iCo has also been building its intellectual property position around the Oral Amphotericin B asset. The company was issued composition of matter and use patents, titled: Formulations for Oral Administration of Therapeutic Agents and Related Methods, issued in the United States, Russia, Singapore, New Zealand and notice of allowance in China. Management is aggressively pursuing further patent issuances in multiple jurisdictions as it moves towards the clinic. Current Amphotericin B product, AmBisome, marketed by Gilead, had sales of $352 million in 2013, but it is severely limited in its application because of its toxicity and IV delivery. An oral delivery platform would open up the market for the treatment of infections and outpatient treatment regimes, as well as developing world treatments where IV is not practical.
iCo Therapeutics Inc. Announces Earnings Results for the Six Months Ended June 30, 2014
Aug 29 14
iCo Therapeutics Inc. announced earnings results for the six months ended June 30, 2014. The company incurred total comprehensive loss of CAD 1,617,040 or loss per share of CAD 0.02 for the six months ended June 30, 2014 compared to a total comprehensive loss of CAD 2,886,831 or loss per share of CAD 0.05 for the six months ended June 30, 2013, representing a decrease of CAD 1,269,791 in comprehensive loss. The decrease in net comprehensive loss is primarily a result of a CAD 259,755 increase in the carrying value of its investment in Immune Pharmaceuticals, as well as a decrease in expenses associated with the iDEAL trial.
iCo Therapeutics Inc. Announces Positive Oral Amphotericin B Study Results
Aug 19 14
iCo Therapeutics Inc. reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta(R), the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy. Memory cells, or white blood cells, from eight HIV-infected subjects with a durable viral suppression using antiretroviral therapy (HAART) were obtained and exposed in vitro to various concentrations of Oral Amp B. Samples from one patient were determined not to be susceptible to reactivation. In the remaining subjects, Oral Amp B demonstrated a reactivation response of HIV viral production in six out of seven in vitro cultures with detectable HIV reservoir. Some HIV reservoirs are not possible to reactivate and this may explain why one culture did not show reactivation response.